Objective: To test the effect of long-term pegfilgrastim on collateral function and myocardial ischaemia in patients with chronic stable coronary artery disease (CAD). Methods: This was a prospective clinical trial with randomized 2:1 allocation to pegfilgrastim or placebo for 6 months. The primary study endpoint was collateral flow index (CFI) as obtained during a 1-minute ostial coronary artery balloon occlusion. CFI is the ratio of mean coronary occlusive divided by mean aortic pressure both subtracted by central venous pressure (mm Hg/mm Hg). Secondary endpoints were signs of myocardial ischaemia determined during the same coronary occlusion, that is quantitative intracoronary (i.c.) ECG ST-segment shift (mV) and the occurrence of angina pectoris. Endpoints were obtained at baseline before and at follow-up after three subcutaneous study drug injections. Results: Collateral flow index in the pegfilgrastim group changed from 0.096 ± 0.076 at baseline to 0.126 ± 0.070 at follow-up (P = 0.0039), while in the placebo group CFI changed from 0.157 ± 0.146 to 0.122 ± 0.043, respectively (P = 0.29); the CFI increment at follow-up was +0.030 ± 0.075 in the pegfilgrastim group and −0.034 ± 0.148 in the placebo group (P = 0.0172). In the pegfilgrastim group, i.c. ECG ST-segment shift changed from +1.23 ± 1.01 mV at baseline to +0.93 ± 0.97 mV at follow-up (P = 0.0049), and in the placebo group, it changed from +0.98 ± 1.02 mV to +1.43 ± 1.09 mV, respectively (P = 0.05). At follow-up, the fraction of patients free from angina pectoris during coronary occlusion had increased in the pegfilgrastim but not in the placebo group. Conclusion: Pegfilgrastim given over the course of 6 months improves collateral function in chronic stable CAD, which is reflected by reduced myocardial ischaemia during a controlled coronary occlusion.
| INTRODUCTION
In the majority of cardiovascular diseases, death is related to infarcted tissue, which is mainly caused by acute vessel occlusion in the context of atherosclerosis. 1 In this situation, outcome depends on infarct size. 2 Myocardial infarct size is-among other methods 2 -reflected by the degree of ECG ST-segment elevation during the acute phase, 3 and is directly determined by the coronary occlusion duration, the ischaemic area at risk for infarct, the lack of collateral supply to the ischaemic region, the absence of preconditioning ischaemic episodes prior to, and the level of myocardial oxygen consumption during the acute coronary event. 4 Accordingly, the rapid restoration of coronary artery patency in acute myocardial infarction reduces infarct size and improves survival. 5 Lowering myocardial oxygen consumption during an infarction by beta-blockers follows the above "equation" of infarct size determinants, but recently, has not been found to limit its extension. 6 Methods of influencing infarct size determinants can be termed myocardial salvage. 7, 8 Aside from the acute reperfusion by percutaneous coronary intervention (PCI) or thrombolysis, other attempts of acute myocardial salvage have not been demonstrated effective, or are-theoretically-not favourable as candidates. That is, promotion of collateral supply to the myocardial area undergoing necrosis takes too long to render it relevantly less ischaemic. 9 As an alternative to acute myocardial salvage, preventive salvage is a promising concept in the context of collateral growth promotion. Collateral growth promotion in patients with coronary artery disease (CAD) and peripheral artery disease by granulocyte-macrophage colony-stimulating factor has been previously investigated and-in part-shown effective, 10, 11 whereby its biological mechanism of action appears to be related cytokine activation. 12 Short-term application of G-CSF has been documented to reduce myocardial ischaemia during a brief coronary artery occlusion, whereby this has been related to augmented collateral function. 13 The present, placebo-controlled study in patients with chronic stable CAD tested the hypothesis that pegylated G-CSF (pegfilgrastim) given over the course of 6 months augments collateral function and intracoronary ECG STsegment shift during a brief and controlled event of myocardial ischaemia.
| METHODS

| Study design and patients
This was a single-centre prospective, longitudinal clinical trial in 54 patients with chronic stable CAD who were randomly assigned to a total of three subcutaneous injections (one injection every 2 months, see under "study protocol") of pegfilgrastim or placebo (ratio 2:1) administered over the course of 6 months. Patients underwent diagnostic coronary angiography in the context of chest pain; the other inclusion criteria were age >18 years, 1-to 3-vessel CAD, signed written informed consent for study participation. Exclusion criteria were acute coronary syndrome, previous myocardial infarction in the vascular region undergoing CFI measurement, severe hepatic or renal failure (creatinine clearance <15 mL/min/1.73 m 2 ). The primary study endpoint was quantitative coronary collateral function (collateral flow index, CFI; see below for calculation) as obtained during a 1-minute proximal coronary artery balloon occlusion at baseline before and at follow-up examination 6 months after the baseline invasive examination (Figure 1 ). Secondary study endpoints were the quantitatively determined intracoronary (i.c.) ECG ST-segment shift, and angina pectoris during the same 1-minute coronary occlusion. Additionally, coronary fractional flow reserve (FFR), and quantitative per cent diameter stenosis of the atherosclerotic lesion undergoing CFI and PCI were obtained.
Inclusion of patients in the study occurred between March 2009 and January 2015.
The study was approved by the ethics committee of the Kanton of Bern, Switzerland, and registered on ClinicalTrials.gov (Identifier NCT00886509).
Reporting of the study conforms to CONSORT-revised statement. 14 
| Cardiac catheterization and coronary angiography
Patients underwent left heart catheterization and coronary angiography for diagnostic purposes from the right femoral artery approach via a 6F introducer sheath. Biplane left ventriculography was performed followed by coronary angiography. Coronary artery stenoses were assessed quantitatively as per cent diameter reduction using the guiding catheter for calibration. Aortic pressure (P ao ) was acquired via a 6F guiding catheter. Central venous pressure (CVP) was measured by a 5F pigtail catheter as right atrial pressure via the right femoral vein. part of the vessel of interest (identical position at baseline and follow-up examination). CFI was determined by simultaneous measurement of mean aortic pressure (P ao , mm Hg), the mean distal coronary artery pressure during balloon occlusion (P occl , mm Hg), and the mean central venous pressure (CVP, mm Hg; Figure 1 ) as measured during the last 30 seconds of the 1-minute coronary balloon occlusion. CFI was calculated as (P occl -CVP) divided by (P ao -CVP). 15 The accuracy of pressure-derived CFI measurements in comparison with ECG signs of myocardial ischaemia during occlusion and of absolute myocardial perfusion measurements has been documented previously.
16,17
| Secondary study endpoints
Signs of myocardial ischaemia were assessed simultaneously to CFI measurement as quantitatively determined i.c. ECG ST-segment shift in mV ( Figure 1) ; the i.c. ECG lead was obtained from the angioplasty guidewire via a crossclamp to a precordial lead. 18 Myocardial ischaemia during the 1-minute coronary occlusions was also characterized by the presence or absence of angina pectoris. Coronary pressure-derived FFR measurements were obtained with the distal pressure sensor wire at identical location as for the CFI measurement.
| Study protocol
Before the diagnostic examination, two puffs of oral isosorbide dinitrate were given. Following diagnostic coronary angiography and at the start of the invasive baseline and follow-up study procedure, all patients received 5000 units of heparin intravenously. All the measurements described below were taken identically at the baseline and follow-up examination. FFR was obtained prior to the primary study endpoint CFI, and in the same vessel as the one undergoing CFI measurement. FFR was determined with the pressure guidewire positioned distally in the non-occluded main vessel of interest using intravenous adenosine at 140 μg/min/kg for hyperaemia induction: FFR = mean distal coronary pressure divided by P ao . At an FFR >0.75, PCI of the coronary artery of interest was deferred to the end of the invasive follow-up examination (ie, after all endpoint measurements), which took place 6 months after the baseline examination; at an FFR ≤0.75, PCI occurred at baseline before endpoint measurements. Endpoint measurements were obtained in the coronary artery undergoing PCI (deferred or not deferred) or in the vessel best accessible for CFI measurement. For CFI, an adequately sized angioplasty balloon catheter was positioned in the ostial part of the vessel while the pressure guidewire remained distally. Before imminent coronary artery balloon occlusion, the patient was asked not to talk and to breathe normally for the following 1.5 minutes (prevention of CVP variability). Coronary balloon inflation occurred at a pressure of 1-2 atmospheres. Complete coronary occlusion was ascertained by angiography. Diagnostic coronary artery balloon occlusion for CFI measurement has been documented to be safe. 19 During the 1-minute occlusion, simultaneous P occl , P ao and CVP were recorded for the calculation of CFI ( Figure 1 ). During the entire procedure, the i.c. ECG obtained from the guidewire was recorded. Immediately after CFI measurement, the patient was asked about the occurrence of angina pectoris during coronary artery balloon occlusion. Following the baseline endpoint measurements, patients were randomly allocated to receiving pegfilgrastim or placebo, the first dose of which was given by the study nurse when the patient arrived on the ward after completion of the invasive procedure. The study medication was administered by subcutaneous injection at study inclusion, and 2 and 4 months later. Pegylated G-CSF (pegfilgrastim, Neulasta ® , Amgen, Thousand Oaks, CA, USA) was administered at a dose of 6 mg per injection (0.6 mL volume). Placebo (saline solution 0.9%) was injected subcutaneously at an identical volume of 0.6 mL.
| Statistical analysis
Sample size calculation was based on values for the primary endpoint CFI found in the previous work by Meier et al 13 , which had CFI changes during follow-up of +0.049 ± 0.062 (mean ± standard deviation) in the G-CSF group, and −0.010 ± 0.060 in the placebo group, respectively (effect size of 0.97). Using a two-sided unpaired Student's t test for inter-individual changes, an alpha level of 0.05, a power of 0.80, and a group allocation ratio of 2:1 (verum : placebo), the calculated total sample size was 40 using the GPower program. Intra-individual comparison of study endpoints between baseline and follow-up examination was carried out using Student's t test for matched pairs. A mixed linear model was employed to assess the within-person correlation of repetitive measurements of continuous variables in >1 coronary artery. Since repetitive intra-individual measurements in different coronary arteries were not shown to be related to the study endpoints, between-group (pegfilgrastim vs placebo) comparison of continuous study endpoints, demographic, clinical, angiographic and hemodynamic variables was performed by unpaired Student's t test. A chi-squared-test was used for comparison of categorical variables among the study groups. Statistical significance was defined at a P-level <0.05. Continuous variables are given as mean and standard deviation.
| RESULTS
Thirty-six patients belonged to the pegfilgrastim group, 18 to the placebo group; in the placebo group, four patients were lost to follow-up, because they refused to undergo the invasive follow-up examination (Table 1 ). All patients received three injections of the study drug.
| Patient characteristics and clinical data at baseline
There were no statistically significant differences between the groups regarding age, gender, body mass index, cardiovascular risk factor prevalence, and cardiovascular medication (Table 1) .
| Hemodynamic and coronary structural and functional data at baseline
There were no statistical differences between the groups in heart rate, left ventricular ejection fraction and end-diastolic pressure, mean arterial and central venous pressure (Table 2) . Study endpoint measurements (CFI, i.c. ECG, angina pectoris, FFR) were performed in 50 coronary arteries of the pegfilgrastim group and in 22 coronary arteries of the placebo group ( Table 2) . The coronary arteries undergoing study endpoint measurements were similarly distributed among the study groups. The number of coronary arteries with stenotic lesions >50% was similar between the groups. PCI was deferred to after follow-up endpoint measurements according to baseline FFR in significantly less patients of the pegfilgrastim than the placebo group ( Table 2 ). The baseline per cent diameter stenoses and FFR values of the coronary arteries undergoing endpoint measurements were similar among the groups.
| Changes of coronary artery structure, function and myocardial ischaemia during follow-up
Both coronary structural and functional stenosis parameters (per cent diameter narrowing and FFR) were similar among the study groups at the follow-up examination, and they had improved in comparison with baseline and in accordance with the patients having been treated by PCI at baseline (Table 2 ).
| Primary study endpoint
Collateral flow index at baseline was lower in the pegfilgrastim group than in the placebo group (Table 2) , and it increased significantly in the pegfilgrastim group, while it remained statistically unchanged in the placebo group (Table 2 and Figure 2 ). The absolute change in CFI from baseline to follow-up examination was significantly higher in the pegfilgrastim than in the placebo group (Table 2 and Figure 3 ).
| Secondary study endpoints
There was a decrease in i.c. ECG ST-segment shift during coronary occlusion from baseline to follow-up examination in the pegfilgrastim but not in the placebo group (Table 2 and Figure 4 ). The absolute change in i.c. ECG ST-shift during follow-up was negative (indicating less ischaemia) in the pegfilgrastim but positive in the placebo group (Table 2 and Figure 3 ). At follow-up vs baseline examination, the fraction of patients free from angina pectoris during the 1-minute coronary artery occlusion had increased in the pegfilgrastim but not in the placebo group ( Figure 5 ). All patients in the G-CSF group experienced flu-like symptoms during the first days after drug injection. Such symptoms could not be observed in the placebo group. No other side effects or adverse events were observed.
| DISCUSSION
This randomized placebo-controlled clinical trial found that pegfilgrastim given over the course of 6 months augmented coronary collateral function, the fact of which was reflected by reduced intracoronary ECG ST-segment shift and less angina pectoris as obtained during a controlled 1-minute proximal coronary artery occlusion.
| Myocardial salvage and ischaemic conditioning
Myocardial salvage following acute coronary occlusion requires prompt and sufficient coronary reperfusion within a time frame of hours as efficiently delivered by acute PCI. 5 Aside from its net effect of myocardial salvage, reperfusion also inflicts tissue injury, which contributes to infarct size extension, but is prevented by ischaemic preconditioning. 20 The clinical relevance of ischaemic preconditioning in acute myocardial infarction is limited, because it has to be applied before the event of coronary occlusion. In this context, brief intermittent ischaemia applied after the onset of reperfusion and termed postconditioning has been also documented to mitigate myocardial injury to a similar extent as ischaemic preconditioning. 21 In particular, G-CSF administered to globally ischaemic rat hearts has been demonstrated to mitigate reperfusion injury, and thus, to act as postconditioning substance. 
G-CSF
Still, the mentioned postconditioning effect of G-CSF obviously does not exert an effect relevant enough to be detectable in terms of augmented LV ejection fraction. 8 In comparison with the coronary circulation, the cerebral circulation at the level of the circle of Willis is better developed with innate collateral arteries. 23 Therefore, chances for successful tissue salvage in the event of acute neck arterial occlusion are better than during acute coronary occlusion. In this context, Duelsner et al 24 found G-CSF given to mice undergoing common carotid artery ligation to have smaller cerebral infarct volumes than animals receiving saline injections, the effect of which was related to augmented cerebral collateral artery growth (arteriogenesis) and cerebrovascular reserve capacity. In patients with CAD presenting much less salvageable myocardial tissue in the event of acute coronary occlusion, the rescue of myocardium has to occur by preventive arteriogenesis. Randomly allocated G-CSF in comparison with placebo given over the course of 2 weeks has been demonstrated to augment coronary collateral function (CFI), and simultaneously, to reduce ECG signs of myocardial ischaemia during a brief coronary balloon occlusion in 52 patients with chronic stable CAD. 13 In a similar study population examined by a non-randomized trial, Ripa et al 25 found that direct intramyocardial injection of vascular endothelial growth factor-A 165 plasmid followed by G-CSF 1 week later did not exert a different effect on myocardial perfusion as obtained 3 months later (single photon emission computed tomography, SPECT) when compared to intramyocardial saline injections. Myocardial perfusion by SPECT is obtained during coronary artery patency (unless there is a chronic occlusion), which does not allow specific collateral function measurement as taken during brief coronary artery balloon occlusion in the study by Meier et al 13 , and in the present investigation. Both the mentioned investigations employed a surrogate endpoint for the amount of myocardium at risk for necrosis or the amount of myocardial ischaemia, that is an estimate of salvageable tissue: 99 m technetium-sestamibi SPECT in the study by Ripa et al 25 , and the quantitative amount of intracoronary STsegment elevation during coronary occlusion. Measurement of the actual amount of salvaged myocardium using, for example late enhancement gadolinium magnetic resonance imaging would have been meaningful only in the setting of acute myocardial infarction. An uncontrolled study by Hill et al 26 in
16 patients with chronic CAD has also not found a beneficial effect on a parameter of myocardial perfusion as obtained during vessel patency and 1 month after treatment with G-CSF.
The primary study endpoint in the present clinical trial, CFI, changed in absolute terms on average by +0.030 (±0.075; standard deviation) among patients receiving pegfilgrastim; this corresponds to a relative increase from baseline of 31%. In comparison, the absolute change in CFI during short-term treatment with G-CSF was +0.049 ± 0.062 (−0.010 ± 0.060 in the placebo group), 13 whereby the CFI responses during follow-up were more consistent, and thus, statistically more relevant in the previous than the actual study. The average CFI response to other forms of coronary arteriogenesis, such as heart rate reduction by ivabradine, 27 physical exercise, 28 external counterpulsation, 29 or extracardiac coronary collateral supply augmentation via the native internal mammary artery 30 compares as follows: +0.059 ± 0.050, +0.069 ± 0.050, and +0.067 ± 0.064, respectively. Thus, the effects appear more sizeable and less variable than the response induced by pegfilgrastim, both of which may be related to a possible fading effect of the proarteriogenic action of pegfilgrastim linked to a longer period of administration over 6 months vs only 6 weeks to 3 months. As this interpretation of our data is speculative, it is, on the other hand, very likely that the arteriogenic effect of pegfilgrastim is not sustainable once administration is stopped. The change in the primary endpoint CFI during follow-up was-dichotomously-associated with the i.c. ECG ST-segment shift change, that is, among patients receiving pegfilgrastim, the CFI increase reflected reduced myocardial ischaemia during the controlled event of ostial coronary occlusion, and thus, potential myocardial salvage. This was supported by a higher proportion of patients free of chest pain during the same event of ischaemia. Linear regression analysis between the continuous variables of CFI change vs i.c. ECG ST-segment shift change revealed, however, only a trend to an inverse association (P = 0.15; data not shown), the fact of which, again, manifests the considerable degree of data variability encountered in both study endpoints.
| Study limitations
An alternative interpretation of the mentioned inconsistent CFI response to 6 months pegfilgrastim is that PCI was deferred-as it would have been ideal-only in half the patients to after follow-up CFI measurement. Among the patients in whom PCI was not postponed, CFI tended to drop in response to removing the hemodynamic obstacle of the coronary stenosis, the pathophysiologic consequence of PCI on collateral function is well known. 31 PCI was initially performed for clinical reasons, that is, because of CAD-related symptoms or an FFR value at baseline below 0.75. This trend towards masking a hypothetical effect of pegfilgrastim on CFI through PCI at baseline tended to conserve the null hypothesis of no study drug effect, and thus, the actual result of a statistically relevant intra-individual CFI increase in the verum group probably underestimated the real effect. Conversely, the interindividual comparison between the verum and placebo group possibly overestimated the real effect of pegfilgrastim because of the drop in CFI during follow-up among patients of the placebo group who had been treated by PCI at baseline. As the only clinical parameter for myocardial ischaemia assessment, angina pectoris during the 1-minute coronary artery balloon occlusion was assessed. It did occur less frequently in the pegfilgrastim group at follow-up examination. Conventional assessment of angina pectoris during daily life, that is, during coronary patency could not be employed as endpoint, because symptomatic relief could not be attributed to an effect of PCI (among the patients undergoing baseline PCI) or of the study drug.
The half-life of pegylated G-CSF is 15-80 hours. Given the 6-months follow-up period in our study and a total of three drug injections every 2 months starting from baseline, the plasma concentration of G-CSF in our patients was zero most of the time and in particular at the time point of follow-up CFI measurement. The design of our study did not account for this pharmacokinetic aspect, but focused primarily on the sustainability of the study drug effect on collateral function.
| CONCLUSION
Pegylated G-CSF given over the course of 6 months improves collateral function in chronic stable CAD, which is reflected by alleviated signs of myocardial ischaemia during a controlled coronary occlusion.
| CLINICAL PERSPECTIVE
If our favourable results are validated in larger studies, then pegylated G-CSF may be considered a treatment option among patients with chronic stable CAD not amenable to conventional revascularisation and/or medical therapy.
